Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2025
Investigating the Challenges of Managing Coexisting Subglottic Stenosis and Bronchopulmonary Diseases Medically Using Computational Modeling.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gao Kerry, Luzum Nathan A, Cohen Seth, Frank-Ito Dennis O
Аннотация
OBJECTIVE: Subglottic stenosis (SGS) coexists with bronchopulmonary disease, complicating topical therapy given the distinct anatomical targets. Optimizing inhaled medication delivery to both regions remain a therapeutic challenge. This study evaluates the ability of orally inhaled aerosol particles to achieve dual‑site deposition in SGS and bronchopulmonary regions.
STUDY DESIGN: Computational modeling of orally inhaled drug particle delivery.
SETTING: Academic Medical Center.
METHODS: Digitally modified airways simulating 8 SGS variants, combining McCaffrey Stage I (5 mm) and II (15 mm) subglottic lengths with Cotton‑Myer Grade I (10%, 30%), Grade II (60%), and Grade III (90%) luminal constrictions. Oral inhalation at 15 L/min and particle transport were simulated for fluticasone propionate (FP; mean aerosol velocity 9.19 m/s, particle size range 1-8 μm) and ciclesonide (CIC; mean aerosol velocity 4.26 m/s, particle size range 1-4 μm) inhaler characteristics, and 6 particle‑size distributions M1(1-5 μm), M2(6-10 μm), M3(1-10 μm) while maintaining the respective parent (CIC and FP) mean aerosol velocity.
RESULTS: In the normal airway, CIC and FP inhalers achieved >80% bronchial deposition but ≤0.02% subglottic delivery. Among modified devices, M2CIC optimized dual targeting, providing the highest subglottic deposition (0.09%) with preserved bronchial efficiency (69.46%). In SGS models, M2CIC and M2FP consistently achieved the most balanced delivery, with maximum deposition of M2CIC = 8.4% and M2FP = 7.86% at subglottic region, and M2CIC = 69.89% and M2FP = 61.02% at bronchial site. M3 variants offered intermediate dual deposition at advanced and Grade III stenosis stages.
CONCLUSION: M2CIC and M2FP inhaler modifications optimized dual-site supporting tailored device strategies for SGS with coexisting bronchopulmonary disease.
STUDY DESIGN: Computational modeling of orally inhaled drug particle delivery.
SETTING: Academic Medical Center.
METHODS: Digitally modified airways simulating 8 SGS variants, combining McCaffrey Stage I (5 mm) and II (15 mm) subglottic lengths with Cotton‑Myer Grade I (10%, 30%), Grade II (60%), and Grade III (90%) luminal constrictions. Oral inhalation at 15 L/min and particle transport were simulated for fluticasone propionate (FP; mean aerosol velocity 9.19 m/s, particle size range 1-8 μm) and ciclesonide (CIC; mean aerosol velocity 4.26 m/s, particle size range 1-4 μm) inhaler characteristics, and 6 particle‑size distributions M1(1-5 μm), M2(6-10 μm), M3(1-10 μm) while maintaining the respective parent (CIC and FP) mean aerosol velocity.
RESULTS: In the normal airway, CIC and FP inhalers achieved >80% bronchial deposition but ≤0.02% subglottic delivery. Among modified devices, M2CIC optimized dual targeting, providing the highest subglottic deposition (0.09%) with preserved bronchial efficiency (69.46%). In SGS models, M2CIC and M2FP consistently achieved the most balanced delivery, with maximum deposition of M2CIC = 8.4% and M2FP = 7.86% at subglottic region, and M2CIC = 69.89% and M2FP = 61.02% at bronchial site. M3 variants offered intermediate dual deposition at advanced and Grade III stenosis stages.
CONCLUSION: M2CIC and M2FP inhaler modifications optimized dual-site supporting tailored device strategies for SGS with coexisting bronchopulmonary disease.